These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25648243)

  • 1. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
    Hammerness PG; Karampahtsis C; Babalola R; Alexander ME
    Expert Opin Drug Saf; 2015 Apr; 14(4):543-51. PubMed ID: 25648243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.
    Hammerness PG; Surman CB; Chilton A
    Curr Psychiatry Rep; 2011 Oct; 13(5):357-63. PubMed ID: 21698412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review.
    Baughman DJ; Watson CM; Beich JW; Herboso MNJ; Cuttie LK; Marlyne AC
    Mil Med; 2024 May; 189(5-6):e1343-e1352. PubMed ID: 37878798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder.
    Houghton R; de Vries F; Loss G
    CNS Drugs; 2020 Jan; 34(1):93-101. PubMed ID: 31768949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.
    Poulton A
    Expert Rev Neurother; 2006 Apr; 6(4):551-61. PubMed ID: 16623654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QTc prolongation after ADHD medication.
    Snircova E; Marcincakova Husarova V; Ondrejka I; Hrtanek I; Farsky I; Nosalova G
    Neuro Endocrinol Lett; 2018 Feb; 38(8):549-554. PubMed ID: 29504733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
    Gerhard T; Winterstein AG; Olfson M; Huang C; Saidi A; Crystal S
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):457-64. PubMed ID: 20232490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.